HC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 178.75% from the company’s previous close. […]
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 178.75% from the company’s previous close. […]
